Application of recombinant saccharomyces cerevisiae to de novo synthesis of homoeriodictyol by using glucose

By integrating specific sites and expressing genes in Saccharomyces cerevisiae, a variety of heterologous pathways were constructed, and the problems of low titers of high sago ol and incomplete synthesis routes in the existing technology were solved, and efficient de novo synthesis of high sago ol is achieved , improving the sustainability and production efficiency of biosynthesis.

CN118910118APending Publication Date: 2024-11-08TIANJIN UNIV SYNTHETIC BIOLOGY FRONTIER RES INST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411279206.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art has low titer and incomplete synthesis of sago phenolic acid in the de novo synthesis of sago phenolic acid, and the traditional acquisition methods have safety and sustainability problems.

Method used

By integrating specific sites and expression genes in Saccharomyces cerevisiae, a variety of heterologous pathways are constructed, including the integration sites of PDC5, TKL2-TEF2, YHRCdelta14, YORWdelta17, ARO10, YNRCdelta9 sites, as well as exogenous and endogenous expression genes, Such as the expression module of TAL, PAL, C4H, ATR2, aroL, PDH1, ROMT-9N135T/I324M, CYB5, ARO4K229L, ARO7G141S, aroL, MET6, SAH1, ADO1, and MET13 genes, optimizes the synthesis route.

Benefits of technology

The highest titer of de novo synthesis of sago chlorophenol was achieved and a new synthesis route was revealed, improving productivity and environmentally friendly biosynthesis methods.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005041505570000021
    Figure BDA0005041505570000021
  • Figure BDA0005041505570000023
    Figure BDA0005041505570000023
  • Figure BDA0005041505570000025
    Figure BDA0005041505570000025
Patent Text Reader

Abstract

The invention relates to the field of bioengineering, in particular to application of recombinant saccharomyces cerevisiae to de novo synthesis of homoeriodictyol by using glucose. The invention provides application of an integration site as a target spot in preparation of homoeriodictyol. And the integration sites comprise one or more of a PDC5 site, a TKL2-TEF2 site, a YHRCDelta 14 site, a YORWDelta 17 site, an ARO10 site and a YNRCDelta 9 site. The highest titer of the homoeriodictyol synthesized from the beginning is realized, and a brand new route for synthesizing the homoeriodictyol from the beginning is disclosed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of bioengineering, and in particular to the application of recombinant saccharomyces cerevisiae in synthesizing homoeriodictyol from scratch by utilizing glucose. Background Art

[0002] Homochoric acid is a flavanone compound derived from North American holy grass, which has antioxidant, anti-inflammatory, antibacterial and anti-cancer effects. In addition, homochoric acid also has a bitter masking effect and has the potential to be used to reduce the bitterness of food and medicine. Therefore, it is crucial to develop sustainable access to homochoric acid. Traditional methods of acquisition mainly include chemical synthesis and plant extraction. However, the seasonality and accessibility of plants make plant extraction methods uncommercial, and the use of toxic reagents and extreme reaction conditions make chemical synthesis methods unsafe and unsustainable. Therefore, biosynthesis of homochoric acid has become a potential production method due to its advantages such as short process cycle, high efficiency and environmental friendliness.

[0003] The biosynthetic pathway of homoeriocarbamide usually starts from the aromatic precursors p-coumaric acid and ferulic acid. The prior art has realized the construction of a heterologous pathway containing 4-p-coumaryl-CoA ligase 4CL from rice and chalcone synthase CHS from barley in Escherichia coli, and realized the synthesis of homoeriocarbamide using ferulic acid, with a titer of 52 mg / L, or the construction of a heterologous pathway containing 4CL from grapes, CHS from Arabidopsis thaliana, and chalcone isomerase CHI from Arabidopsis thaliana, and synthesized homoeriocarbamide using glycerol as a carbon source and ferulic acid as an intermediate product, with a titer of 17 mg / L. In addition, the prior art has also realized the synthesis of homoeriocarbamide using p-coumaric acid as a precursor in Saccharomyces cerevisiae. The pathways mainly include 4CL from parsley, CHS from petunia, CHI from alfalfa, flavonoid 3'-monooxygenase F3'H and cytochrome P450 reductase ATR1 from Arabidopsis, and 3'-O-methyltransferase ROMT-9 from Japanese rice. Using metabolic engineering strategies and rational design and modification of enzymes, the titer of high eriodictyol in shake flask fermentation can reach 1.0mmol / l.

[0004] Although the existing technology has achieved the de novo synthesis of homoeriodictyol, the titer is low. At the same time, the synthesis route of de novo synthesis of homoeriodictyol has not yet been fully revealed. Summary of the invention

[0005] In view of this, the present invention provides the use of recombinant Saccharomyces cerevisiae to synthesize homoeriodictyol from scratch using glucose. The present invention achieves the highest titer of homoeriodictyol synthesized from scratch and discloses a new route for synthesizing homoeriodictyol from scratch.

[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0007] The present invention provides the use of the integration site as a target in the preparation of homoeriodictyol;

[0008] The integration sites include: one or more of a PDC5 site, a TKL2-TEF2 site, a YHRCdelta14 site, a YORWdelta17 site, an ARO10 site and a YNRCdelta9 site.

[0009] In some embodiments of the present invention, in the above application, the sequence of the PDC5 site is as shown in SEQ ID NO: 10: atgtctgaaataaccttaggtaaatatttatttgaaagattgagccaagtcaactgtaacaccgtcttcggtttgccaggtgactttaac ttgtctctttttggataagctttatgaagtcaaaggtatgagatgggctggtaacgctaacgaattgaacgctgcctatgctgctgatggttacgct

[0010]

[0011] In some embodiments of the present invention, in the above application, the sequence of the TKL2-TEF2 site is as shown in SEQ ID NO: 11: aacatcaatcatgcggttgc.

[0012] In some embodiments of the present invention, in the above application, the sequence of the YHRCdelta14 site is as shown in SEQ ID NO: 12:

[0013] In some embodiments of the present invention, in the above application, the sequence of the YORWdelta17 site is shown in SEQ ID NO: 13:

[0014] In some embodiments of the present invention, in the above application, the sequence of the ARO10 site is as shown in SEQ ID NO: 14:

[0015]

[0016] In some embodiments of the present invention, in the above application, the sequence of the YNRCdelta9 site is as shown in SEQ ID NO: 15:

[0017] The present invention also provides the use of the expression gene in the preparation of homoeriodictyol;

[0018] The expressed genes include: exogenous expressed genes and / or endogenous expressed genes;

[0019] The exogenous expression genes include: TAL gene, PAL gene, C4H gene, ATR2 gene, aroL gene, PDH1 gene, ROMT-9 N135T / I324M gene and one or more of the MTHFR gene;

[0020] The endogenous expression genes include: CYB5 gene, ARO4 K229L Gene, ARO7 G141S One or more of gene, MET6 gene, SAH1 gene, ADO1 gene and MET13 gene.

[0021] In some embodiments of the present invention, in the above application, the TAL gene has:

[0022] (1), the nucleotide sequence shown in SEQ ID NO: 1; or

[0023] (2) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (1), and having the same or similar function as the nucleotide sequence shown in (1); or

[0024] (3) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (1) or (2); or

[0025] The PAL gene has:

[0026] (4) the nucleotide sequence shown in SEQ ID NO: 2; or

[0027] (5) a nucleotide sequence obtained by substituting, deleting or adding one or more bases of the nucleotide sequence shown in (4), and having the same or similar function as the nucleotide sequence shown in (4); or

[0028] (6) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (4) or (5); or

[0029] The C4H gene has:

[0030] (7), the nucleotide sequence shown in SEQ ID NO: 3; or

[0031] (8) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as the nucleotide sequence shown in (7); or

[0032] (9), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (7) or (8); or

[0033] The ATR2 gene has:

[0034] (10), the nucleotide sequence shown in SEQ ID NO: 4; or

[0035] (11) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (10), and having the same or similar function as the nucleotide sequence shown in (10); or

[0036] (12) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (10) or (11); or

[0037] The CYB5 gene has:

[0038] (13), the nucleotide sequence shown in SEQ ID NO: 5; or

[0039] (14) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (13), and having the same or similar function as the nucleotide sequence shown in (13); or

[0040] (15) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (13) or (14); or

[0041] The ARO4 K229L Genes have:

[0042] (16), the nucleotide sequence shown in SEQ ID NO: 6; or

[0043] (17) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (16), and having the same or similar function as the nucleotide sequence shown in (16); or

[0044] (18), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (16) or (17); or

[0045] The ARO7 G141S Genes have:

[0046] (19), the nucleotide sequence shown in SEQ ID NO:7; or

[0047] (20) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (19), and having the same or similar function as the nucleotide sequence shown in (19); or

[0048] (21), a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (19) or (20); or

[0049] The aroL gene has:

[0050] (22), the nucleotide sequence shown in SEQ ID NO: 8; or

[0051] (23) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (22), and having the same or similar function as the nucleotide sequence shown in (22); or

[0052] (24), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (22) or (23); or

[0053] The PDH1 gene has:

[0054] (25), the nucleotide sequence shown in SEQ ID NO:9; or

[0055] (26) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (25), and having the same or similar function as the nucleotide sequence shown in (25); or

[0056] (27) A nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (25) or (26).

[0057] In some embodiments of the present invention, in the above application, the sequence of the TAL gene is as shown in SEQ ID NO: 1:

[0058] In some embodiments of the present invention, in the above application, the sequence of the PAL gene is shown in SEQ ID NO: 2:

[0059]

[0060] In some embodiments of the present invention, in the above application, the sequence of the C4H gene is shown in SEQ ID NO: 3:

[0061]

[0062] In some embodiments of the present invention, in the above application, the sequence of the ATR2 gene is shown in SEQ ID NO:4:

[0063]

[0064] In some embodiments of the present invention, in the above application, the sequence of the CYB5 gene is shown in SEQ ID NO:5:

[0065] In some embodiments of the present invention, the ARO4 K229L The sequence of the gene is shown in SEQ ID NO:6:

[0066]

[0067] In some embodiments of the present invention, the ARO7 G141S The sequence of the gene is shown in SEQ ID NO:7:

[0068] In some embodiments of the present invention, in the above application, the sequence of the aroL gene is shown in SEQ ID NO: 8:

[0069] In some embodiments of the present invention, in the above application, the sequence of the PDH1 gene is shown in SEQ ID NO:9:

[0070]

[0071] The present invention also provides an expression module, including: one or more of the first expression module to the fourteenth expression module;

[0072] The first expression module includes: the TAL gene used in the above application;

[0073] The second expression module includes: the PAL gene of the above application;

[0074] The third expression module includes: the C4H gene used above;

[0075] The fourth expression module includes: the ATR2 gene used above;

[0076] The fifth expression module includes: the CYB5 gene used above;

[0077] The sixth expression module includes: the ARO4 of the above application K229L Gene;

[0078] The seventh expression module includes: the ARO7 of the above application G141S Gene;

[0079] The eighth expression module comprises: the aroL gene of the above application;

[0080] The ninth expression module comprises: the PDH1 gene used above;

[0081] The tenth expression module comprises: the ROMT-9 of the above application N135T / I324M Gene;

[0082] The eleventh expression module includes: the MET6 gene used above;

[0083] The twelfth expression module includes: the SAH1 gene used above;

[0084] The thirteenth expression module includes: the ADO1 gene used above;

[0085] The fourteenth expression module includes: the MET13 gene and the MTHFR gene used above.

[0086] In some embodiments of the present invention, the above-mentioned expression module further comprises: a promoter and a terminator;

[0087] The promoter includes: TEF1 , P GPM1 , P TPI1 and P TDH3 One or more of;

[0088] The terminator includes: ADH1 , T TEF2 , T CPS1 and T PGK1 One or more of .

[0089] In some embodiments of the present invention, in the above expression module, the P TEF1 The sequence is shown in SEQ ID NO: 16:

[0090] In some embodiments of the present invention, in the above expression module, the P GPM1 The sequence is shown in SEQ ID NO: 17:

[0091] In some embodiments of the present invention, in the above expression module, the P TPI1 The sequence is shown in SEQ ID NO: 18:

[0092] In some embodiments of the present invention, in the above expression module, the P TDH3 The sequence is shown in SEQ ID NO: 19:

[0093] In some embodiments of the present invention, in the above expression module, the T ADH1 The sequence is shown in SEQ ID NO: 20:

[0094] In some embodiments of the present invention, in the above expression module, the T TEF2 The sequence is shown in SEQ ID NO:21:

[0095] In some embodiments of the present invention, in the above expression module, the T CPS1 The sequence is shown in SEQ ID NO:22:

[0096] In some embodiments of the present invention, in the above expression module, the T PGK1 The sequence is shown in SEQ ID NO:23:

[0097] In some embodiments of the present invention, in the above expression module, the ROMT-9 N135T / I324M The gene, the MTHFR gene, the MET6 gene, the SAH1 gene, the ADO1 gene and the MET13 gene are derived from the patent with application number "202310747742.X" and invention name "Application of recombinant brewer's yeast in producing homocolumnol using p-coumaric acid".

[0098] In some embodiments of the present invention, in the above expression module, the ROMT-9 N135T / I324M The sequence of the gene is shown in SEQ ID NO:24:

[0099]

[0100] In some embodiments of the present invention, in the above expression module, the sequence of the MTHFR-MET13 chimera gene is as shown in SEQ ID NO: 25:

[0101] In some embodiments of the present invention, in the above expression module, the sequence of the MET6 gene is as shown in SEQ ID NO: 26:

[0102] In some embodiments of the present invention, in the above expression module, the sequence of the SAH1 gene is as shown in SEQ ID NO: 27:

[0103]

[0104] In some embodiments of the present invention, in the above expression module, the sequence of the ADO1 gene is as shown in SEQ ID NO: 28:

[0105] In some embodiments of the present invention, in the above expression modules, the first expression module is expressed at the above PDC5 site;

[0106] The second expression module, the third expression module, the fourth expression module and the fifth expression module are expressed at the above-mentioned TKL2-TEF2 site;

[0107] The sixth expression module and the seventh expression module are expressed at the above-mentioned YHRCdelta14 site;

[0108] The eighth expression module and the ninth expression module are expressed at the YORWdelta17 site;

[0109] The tenth expression module is expressed at the ARO10 site;

[0110] The eleventh expression module, the twelfth expression module, the thirteenth expression module and the fourteenth expression module are expressed at the YNRCdelta9 site.

[0111] The present invention also provides a strain, into which the above expression module is introduced.

[0112] In some embodiments of the present invention, in the above-mentioned strains, the chassis strain includes: Saccharomyces cerevisiae.

[0113] The present invention also provides the use of the expression module and / or the strain in the preparation of homoeriodictyol.

[0114] The present invention also provides a method for preparing homoeriodictyol, which comprises inoculating and culturing the above-mentioned strain to obtain the homoeriodictyol.

[0115] The invention realizes the highest titer of de novo synthesis of homoeriodictyol and discloses a completely new route for de novo synthesis of homoeriodictyol. BRIEF DESCRIPTION OF THE DRAWINGS

[0116] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0117] Figure 1 A pathway for the de novo synthesis of homoeriodictyol was shown

[0118] Figure 2 The results showed that the production of eriodictyol could be increased; the effects of introducing tyrosine pathway, phenylalanine pathway and optimizing shikimic acid pathway on the production of eriodictyol were investigated;

[0119] Figure 3 The results showed that the production of eriodictyol could be improved; the effect of introducing the methylation pathway on the high eriodictyol pathway was investigated. DETAILED DESCRIPTION

[0120] The invention discloses application of recombinant saccharomyces cerevisiae to synthesize homoeriochoric acid from scratch by utilizing glucose.

[0121] It should be understood that the expression "one or more of..." includes each of the items recited after the expression individually and in various different combinations of two or more of the recited items, unless otherwise understood from the context and usage. The expression "and / or" in combination with three or more recited items should be understood to have the same meaning, unless otherwise understood from the context.

[0122] The use of the terms "comprising", "having" or "containing", including their grammatical synonyms, should generally be understood as open and non-restrictive, for example not excluding other unrecited elements or steps, unless otherwise specifically stated or otherwise understood from the context.

[0123] It should be understood that the order of steps or the order in which certain actions are performed is not important as long as the present invention remains operable. In addition, two or more steps or actions may be performed simultaneously.

[0124] The use of any and all examples or exemplary language, such as "for example" or "including", herein is intended only to better illustrate the invention and does not limit the scope of the invention unless otherwise claimed. No language in this specification should be construed as indicating that any non-claimed element is essential to the practice of the invention.

[0125] In addition, the numerical ranges and parameters used to define the present invention are approximate values, and the relevant values ​​in the specific embodiments have been presented as accurately as possible. However, any numerical value inherently inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise expressly stated, it should be understood that all ranges, quantities, values ​​and percentages used in this disclosure are modified by "about". Here, "about" generally means that the actual value is within plus or minus 10%, 5%, 1% or 0.5% of a specific value or range.

[0126] Example of ROMT-9 N135T / I324M The method of integrating genes into the ARO10 site of the yeast genome mainly utilizes CRISPR and homologous recombination technology.

[0127] First build ROMT-9 N135T / I324M Gene expression cassette: P TPI1 -ROMT-9 N135T / I324M -T CPS1 .

[0128] Promoter P TPI1 The yeast genome was used as a template and primers: tatatctaggaacccatcaggt (as shown in SEQ ID NO: 29) and ttttagtttatgtatgtgttttttgtagt (as shown in SEQ ID NO: 30) were used for amplification. The selection principle of the upper primer in the amplification primer is to select a primer of 17-30 bp at the 5' end of the provided promoter sequence, and to ensure that its annealing temperature Tm value is between 52-55° C. The selection principle of the lower primer is to select a primer at the 3' end of the promoter sequence, and the length and Tm value are consistent with the upper primer selection principle, but the Tm value difference between the upper and lower primers must not exceed 5° C.

[0129] ROMT-9 N135T / I324M The gene (synthesized by Qingke Biotechnology Co., Ltd.) was amplified using primers aaacacatacataaactaaaaGCATGG GTTCTACAGCAGCA (as shown in SEQ ID NO: 31) and CTTGGGCTATTGAATTCACTAAGT AAGCgcgcaatgattgaatagtc (as shown in SEQ ID NO: 32). N135T / I324MThe 5' ends of the upper and lower primers carry 20bp regions homologous to the promoter and terminator, respectively. Gene amplification primers consist of two parts, one part is homologous to the gene, and the other part is homologous to the promoter or terminator element. The selection principle of the part homologous to the gene is consistent with the selection principle of the promoter amplification primer. After the selection is completed, add 20-30bp homologous to the downstream end of the promoter to the 5' end of the upper primer of the gene (the Tm value of this part is above 50°C), and add 20-30bp homologous to the upstream front end of the terminator to the 5' end of the lower primer of the gene (the Tm value of this part is above 50°C).

[0130] Terminator T CPS1 The yeast genome was used as a template and primers: gcgcaatgattgaatagtcaaa (shown in SEQ ID NO: 33) and agaataggtttcgttttctggaa (shown in SEQ ID NO: 34) were used for amplification. The selection method of the terminator amplification primers was the same as that of the promoter amplification primers.

[0131] The above three amplified fragments were overlapped by PCR to obtain ROMT-9 N135T / I324M expression cassette.

[0132] Next, the yeast genome was used as a template to amplify the connector fragment used for homologous recombination.

[0133] The selection principle of Linker1-1 is 400bp upstream of the genomic insertion site. The selection principle of amplification primers is consistent with the above promoter selection principle. It should be noted that the 5' end of the lower primer of Linker1-1 needs to add 20-30bp homologous to the front end of the upstream promoter (the Tm value of this part is above 50°C). Linker1-1 is amplified with primers CATTTGGTAGTAGGCT TAGGC (as shown in SEQ ID NO:35) and AGATAACAAAGAAACTCCCTTAAGCtcttgcccatcag attgatg (as shown in SEQ ID NO:36), and the lower primer carries 20bp homologous to the promoter.

[0134] The selection principle of Linker2-1 is 400bp downstream of the genomic insertion site. The selection principle of amplification primers is consistent with the above promoter selection principle. It should be noted that the 5' end of the upper primer of Linker2-1 needs to add 20-30bp homologous to the most downstream end of the terminator (the Tm value of this part is above 50°C). Linker2-1 is amplified using primers aagaataggtttcgttttctggaaCT TGTGGGCGCAATTATAAAAC (as shown in SEQ ID NO:37) and GCAGACATTTAGCAGATG TAGG (as shown in SEQ ID NO:38), and the upper primer has 20bp homologous to the terminator.

[0135] Overlap PCR was performed between linker1-1 and the promoter fragment, and overlap PCR was performed between linker2-1 and the terminator fragment to obtain linker1 and linker2, respectively.

[0136] Next, search for the first 20 bp of the pam sequence (NGG) at the ARO10 site as the gRNA, search for the target insertion site on the website https: / / yeastgenome.org / , and obtain the sequence of the insertion site. The specific selection method is to enter the sequence of the insertion site into the "Target asequence" input box of the website https: / / www.atum.bio / eCommerce / cas9 / input, select "Saccharomyces cerevisiae" for species, select "NGG" for PAM, and select "Wild-type Cas9" for Iwant. After the settings are completed, select search and select the gRNA sequence with the highest score in the results.

[0137] In this example, the gRNA is: CGCTTGCTCGGTAGCCTACT (as shown in SEQ ID NO: 39). Next, the CRISPR-gRNA-Cas9-his plasmid is combined with ROMT-9 N135T / I324MThe expression cassette, linker1, and linker2 were transformed into yeast, and then spread on yeast basal medium (SC-his) and cultured for 3-4 days to obtain a recombinant yeast strain. The first pair of verification primers were found upstream of the insertion site and the gene, and the length of the verification interface 1 was about 1000bp. The second pair of verification primers were found downstream of the insertion site and the gene, and the length of the verification interface 2 was about 1000bp. The selection method of the verification primers is to select a 20-30bp verification upper primer (Tm value at 52-55°C) about 100bp upstream of linker1-1 as the upper primer of the first pair of verification primers. The lower primer of the first pair of verification primers is selected in the upstream part of the inserted gene fragment, and the length and Tm value are consistent with the above. Note that the sequence length separated by this pair of primers is about 1000-2000bp. Select a 20-30bp verification upper primer (Tm value at 52-55°C) about 100bp downstream of linker2-1 as the lower primer of the second pair of verification primers. The upper primer of the second pair of verification primers is selected in the downstream part of the inserted gene fragment, and the length and Tm value are consistent with the above. Note that the sequence length between this pair of primers is about 1000-2000bp.

[0138] The first pair of verification primers in this example are: ACACCTCATGTAGCTTCCTTATTAA (as shown in SEQ ID NO: 40), TGCTGCTGTAGAACCCAT (as shown in SEQ ID NO: 41). The second pair of verification primers are: GAGA GAATTCAGAGAATTGGCT (as shown in SEQ ID NO: 42), CTTTGTTAGAGCCAATGATT TCG (as shown in SEQ ID NO: 43).

[0139] The linker sequence selection criteria in the present invention are: for genome-integrated genes, the linker selects a fragment 400 bp upstream and downstream of the site; for knocked-out genes, the linker selects a fragment 400 bp upstream and downstream of the knocked-out gene.

[0140] According to the above method, ROMT-9 N135T / I324M The gene was integrated into the yeast genome at the ARO10 locus.

[0141] The integration of the expression cassette into the gene locus in Examples 1 to 3 of the present invention is the same as the above method, except that the elements in the expression cassette are replaced.

[0142] In Examples 1 to 3 of the present invention, all the raw materials and reagents used can be purchased from the market.

[0143] The present invention will be further described below in conjunction with embodiments:

[0144] Example 1

[0145] The present invention first constructs a pathway for synthesizing p-coumaric acid from tyrosine and phenylalanine in the Yeri001 strain (derived from patent application number: 202310747742.X) that can produce eriodictyol from previous studies. The specific method is:

[0146] The expression cassette of tyrosine ammonia lyase TAL from Flavobacterium johnsonii (including promoter P TEF1 -TAL gene-terminator T ADH1 ) was integrated into the genomic locus PDC5 of Yeri001 (i.e., the entire PDC5 gene was deleted) to obtain the YTAL001 strain, and then the phenylalanine ammonia lyase PAL (including: P TEF1 -PAL gene-terminator T ADH1 ), trans-cinnamate 4-monooxygenase C4H (including: promoter P GPM1 -C4H gene-terminator T TEF2 ), cytochrome P450 reductase 2ATR2 (including: promoter P TPI1 -ATR2 gene-terminator T CPS1 ), cytochrome b5 from Saccharomyces cerevisiae (including promoter P TDH3 -CYB5 gene-terminator T PGK1 ) was integrated into the genomic loci between TKL2 and TEF2 to obtain the YTP001 strain.

[0147] Example 2

[0148] This example strengthens the de novo synthesis of eriodictyol and optimizes the shikimic acid pathway of the above-mentioned recombinant strain YTP001.

[0149] 3-deoxy-D-arabinose-heptulose-7-phosphate ARO4 K229L Expression cassette (including promoter P GPM1 -ARO4 K229L Gene-Terminator T TEF2 ) and chorismate mutase ARO7 G141S Expression cassette (including promoter P TPI1 -ARO7 G141S Gene-Terminator T CPS1 ) was integrated into the genomic locus YHRCdelta14 (i.e., the entire sequence of this locus was deleted) to release the feedback inhibition, and the YTP002 strain was obtained. Then, the expression cassette of the shikimate kinase aroL from Escherichia coli (including: promoter P TDH3 -aroL gene-terminator T PGK1 ) and an expression cassette of prephenate dehydrogenase PDH1 from Medicago truncatula (including: promoter P GPM1 -PDH1 gene-terminator TTEF2 ) was integrated into the genomic site YORWdelta17 (i.e., the entire sequence of this site was deleted) to strengthen the rate-limiting step in the shikimate pathway and obtain the YTP004 strain.

[0150] Table 1

[0151] strain Eriochoride production YTAL001 15.2mg / L YTP001 110.0mg / L YTP002 130.8mg / L YTP004 209.2mg / L

[0152] Example 3

[0153] After strengthening the synthesis pathway of eriodictyol, ROMT-9 was integrated into the genomic locus ARO10 of the above strain (i.e., the entire sequence of this locus was deleted). N135T / I324M Expression cassette (including promoter P TPI1 -ROMT-9 N135T / I324M Gene-Terminator T CPS1 ), obtain the YTP007 strain, and integrate the yeast endogenous gene homocysteine ​​S-methyltransferase MET6 (including: promoter P TPI1 -MET6 gene-terminator T CPS1 ), S-adenosyl-l-cysteine ​​hydrolase SAH1 (including: promoter P GPM1 -SAH1 gene-terminator T TEF2 ), adenosine kinase ADO1 (including: promoter P TEF1 -ADO1 gene-terminator T ADH1 ), methylenetetrahydrofolate reductase MET13 and a chimeric expression cassette of methylenetetrahydrofolate reductase MTHFR from Arabidopsis thaliana (including: promoter P TDH3 -MET13 gene-MTHFR gene-terminator T PGK1 ), and obtained the YTP008 strain. The YTP008 strain was cultured on YPD medium with an initial OD600 of 0.1 for 72 h, and the construction of a de novo synthesis pathway of homoeriodictyol was achieved, and the obtained product titer was 174.0 mg / L.

[0154] Table 2

[0155] strain High eriodictyol production YTP007 137.6mg / L YTP008 174.0mg / L

[0156] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of integration sites as targets in the preparation of homoeriodictyol; The integration sites include: One or more of the PDC5 site, the TKL2-TEF2 site, the YHRCdelta14 site, the YORWdelta17 site, the ARO10 site and the YNRCdelta9 site.

2. Application of the expressed gene in the preparation of homoeriodictyol; The expressed genes include: exogenous expressed genes and / or endogenous expressed genes; The exogenous expression genes include: TAL gene, PAL gene, C4H gene, ATR2 gene, aroL gene, PDH1 gene, ROMT-9 N135T / I324M gene and one or more of the MTHFR gene; The endogenous expression genes include: CYB5 gene, ARO4 K229L Gene, ARO7 G141S One or more of gene, MET6 gene, SAH1 gene, ADO1 gene and MET13 gene.

3. The use according to claim 2, characterized in that The TAL genes have: (1), the nucleotide sequence shown in SEQ ID NO: 1; or (2) a nucleotide sequence obtained by substituting, deleting or adding one or more bases to the nucleotide sequence shown in (1), and having the same or similar function as the nucleotide sequence shown in (1); or (3) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (1) or (2); or The PAL gene has: (4) the nucleotide sequence shown in SEQ ID NO: 2; or (5) a nucleotide sequence obtained by substituting, deleting or adding one or more bases of the nucleotide sequence shown in (4), and having the same or similar function as the nucleotide sequence shown in (4); or (6) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (4) or (5); or The C4H gene has: (7), the nucleotide sequence shown in SEQ ID NO: 3; or (8) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (7), and having the same or similar function as the nucleotide sequence shown in (7); or (9), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (7) or (8); or The ATR2 gene has: (10), the nucleotide sequence shown in SEQ ID NO: 4; or (11) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (10), and having the same or similar function as the nucleotide sequence shown in (10); or (12) a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (10) or (11); or The CYB5 gene has: (13), the nucleotide sequence shown in SEQ ID NO: 5; or (14) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (13), and having the same or similar function as the nucleotide sequence shown in (13); or (15) a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (13) or (14); or The ARO4 K229L Genes have: (16), the nucleotide sequence shown in SEQ ID NO: 6; or (17) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (16), and having the same or similar function as the nucleotide sequence shown in (16); or (18), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (16) or (17); or The ARO7 G141S Genes have: (19), the nucleotide sequence shown in SEQ ID NO:7; or (20) A nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (19), and having the same or similar function as the nucleotide sequence shown in (19); or (21), a nucleotide sequence having at least 80% identity with the nucleotide sequence shown in (19) or (20); or The aroL gene has: (22), the nucleotide sequence shown in SEQ ID NO: 8; or (23) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (22), and having the same or similar function as the nucleotide sequence shown in (22); or (24), a nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (22) or (23); or The PDH1 gene has: (25), the nucleotide sequence shown in SEQ ID NO:9; or (26) a nucleotide sequence obtained by replacing, deleting or adding one or more bases of the nucleotide sequence shown in (25), and having the same or similar function as the nucleotide sequence shown in (25); or (27) A nucleotide sequence that is at least 80% identical to the nucleotide sequence shown in (25) or (26).

4. An expression module, characterized in that include: One or more of the first expression module to the fourteenth expression module; The first expression module comprises: the TAL gene used as claimed in claim 2 or 3; The second expression module comprises: the PAL gene used as claimed in claim 2 or 3; The third expression module comprises: the C4H gene used as claimed in claim 2 or 3; The fourth expression module comprises: the ATR2 gene used as claimed in claim 2 or 3; The fifth expression module comprises: the CYB5 gene used as claimed in claim 2 or 3; The sixth expression module includes: the ARO4 used as claimed in claim 2 or 3 K229L Gene; The seventh expression module comprises: the ARO7 as used in claim 2 or 3 G141S Gene; The eighth expression module comprises: the aroL gene used as claimed in claim 2 or 3; The ninth expression module comprises: the PDH1 gene used as claimed in claim 2 or 3; The tenth expression module comprises: the ROMT-9 as used in claim 2 or 3 N135T / I324M Gene; The eleventh expression module comprises: the MET6 gene used as claimed in claim 2 or 3; The twelfth expression module comprises: the SAH1 gene used as claimed in claim 2 or 3; The thirteenth expression module comprises: the ADO1 gene used as claimed in claim 2 or 3; The fourteenth expression module includes: the MET13 gene and the MTHFR gene used as claimed in claim 2 or 3.

5. The expression module according to claim 4, characterized in that Also includes: promoters and terminators; The promoter includes: TEF1 , P GPM1 , P TPI1 and P TDH3 One or more of; The terminator includes: ADH1 、T TEF2 、T CPS1 and T PGK1 One or more of .

6. The expression module according to claim 4 or 5, characterized in that The first expression module is expressed at the PDC5 site as claimed in claim 1; The second expression module, the third expression module, the fourth expression module and the fifth expression module are expressed at the TKL2-TEF2 site according to claim 1; The sixth expression module and the seventh expression module are expressed at the YHRCdelta14 site as claimed in claim 1; The eighth expression module and the ninth expression module are expressed at the YORWdelta17 site as claimed in claim 1; The tenth expression module is expressed at the ARO10 site as claimed in claim 1; The eleventh expression module, the twelfth expression module, the thirteenth expression module and the fourteenth expression module are expressed at the YNRCdelta9 site as claimed in claim 1.

7. A strain characterized in that The expression module according to any one of claims 4 to 6 is introduced into the chassis strain.

8. Use of the expression module according to any one of claims 4 to 6 and / or the strain according to claim 7 in the preparation of homoeriodictyol.

9. A method for preparing homoeriodictyol, characterized in that: The strain as claimed in claim 7 is inoculated and cultured to obtain the homoeriochoride.